Skip to main content

Table 2 Follow-up parameters in part II of the study (double-blind)

From: Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial

 

Day 1

Day 3

Day 7

Day 18

Day 30

 

rhEPO

Placebo

rhEPO

Placebo

rhEPO

Placebo

rhEPO

Placebo

rhEPO

Placebo

Hematocrit (%)

43.10 ± 0.90

42.70 ± 1.39

41.70 ± 1.00

40.20 ± 1.27

41.40 ± 1.46

38.00 ± 1.91

41.80 ± 1.23

38.60 ± 1.61

42.00 ± 1.06

40.50 ± 1.25

Red blood cell count (106/µl)

4.80 ± 0.12

4.70 ± 0.16

4.60 ± 0.11

4.40 ± 0.13

4.50 ± 0.16

4.20 ± 0.22

4.60 ± 0.15

4.20 ± 0.19

4.70 ± 0.14

4.40 ± 0.16

Thrombocyte count (×103/µl)

226.20 ± 14.12

213.50 ± 11.69

218.00 ± 15.56

218.90 ± 14.14

243.20 ± 19.78

239.40 ± 13.17

344.50 ± 26.61

362.30 ± 39.46

246.40 ± 19.62

282.10 ± 20.76

Serum EPO* (U/l)

10.60 ± 1.58

12.00 ± 1.09

5148.40 ± 1094.64

19.50 ± 2.75

24.40 ± 4.37

31.60 ± 12.59

8.00 ± 1.00

28.50 ± 11.73

14.90 ± 3.56

21.00 ± 5.64

  1. *Determined in the first nine patients of each group only.